PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.\', \'Department of Laboratory Animal Medicine, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.\', \'Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Department of Infection Control, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan.\', \'Sapporo Laboratory, EVEC, Inc., Hokkaido, Japan.\', \'Department of Academic-Industrial Partnerships Promotion, Center of Clinical Science, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Sapporo Laboratory, EVEC, Inc., Hokkaido, Japan. Electronic address: r-miura@evec.jp.\', \'Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: zakay@ri.ncgm.go.jp.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0166-3542(22)00066-310.1016/j.antiviral.2022.105297
?:hasPublicationType
?:journal
  • Antiviral research
is ?:pmid of
?:pmid
?:pmid
  • 35341809
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.925
?:rankingScore_hIndex
  • 105
is ?:relation_isRelatedTo_publication of
?:title
  • Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all